Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

2.5K
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
2.5K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

2.3K
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
2.3K
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

787
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
787
Antifungal Agents01:15

Antifungal Agents

131
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
131
Anthelminthic Agents01:15

Anthelminthic Agents

115
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
115

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection.

Antiviral therapy·2014
Same author

Discovery and development of first in class antifungal caspofungin (CANCIDAS®)--a case study.

Natural product reports·2013
Same author

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.

The Lancet. Infectious diseases·2013
Same author

Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.

AIDS research and human retroviruses·2013
Same author

Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004).

Journal of acquired immune deficiency syndromes (1999)·2012
Same author

Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: a brief report.

International journal of antimicrobial agents·2011

Related Experiment Video

Updated: May 5, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

11.9K

Advances in antifungal therapy.

Carole A Sable1, Kim M Strohmaier, Jeffrey A Chodakewitz

  • 1Novexel SA, Romainville, France. carole.sable@novexel.com

Annual Review of Medicine
|October 31, 2007
PubMed
Summary

Invasive fungal infections (IFIs) are rising in immunocompromised patients. Advances in antifungal drugs and diagnostics offer new hope, but research continues for optimal treatment strategies.

Area of Science:

  • Infectious Diseases
  • Mycology
  • Clinical Medicine

Background:

  • Increasing prevalence of invasive fungal infections (IFIs) over 30 years.
  • IFIs are linked to significant patient morbidity and mortality.
  • Rise in immunocompromised hosts contributes to IFI incidence.

Purpose of the Study:

  • To review recent advances in antifungal therapy and diagnostics for IFIs.
  • To highlight ongoing research into novel treatment strategies for IFIs.
  • To address the need for optimal management of serious fungal infections.

Main Methods:

  • Review of recent advancements in antifungal pharmacotherapy.
  • Analysis of new diagnostic tools for IFIs.
  • Discussion of emerging treatment strategies like combination and pre-emptive therapy.

More Related Videos

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

20.2K
Quantifying the Antifungal Activity of Peptides Against Candida albicans
06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

2.8K

Related Experiment Videos

Last Updated: May 5, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
08:45

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance

Published on: December 28, 2017

11.9K
Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
08:54

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds

Published on: February 14, 2018

20.2K
Quantifying the Antifungal Activity of Peptides Against Candida albicans
06:45

Quantifying the Antifungal Activity of Peptides Against Candida albicans

Published on: January 13, 2023

2.8K

Main Results:

  • Introduction of broad-spectrum triazoles (voriconazole, posaconazole) and echinocandins (caspofungin, micafungin, anidulafungin).
  • Integration of galactomannan and beta-glucan tests into diagnostic criteria (EORTC/MSG).
  • Investigation of combination and pre-emptive therapy approaches.

Conclusions:

  • Significant progress in antifungal treatments and diagnostics for IFIs.
  • Unanswered questions persist regarding optimal management of serious fungal infections.
  • Continued research is crucial for developing new therapies and management strategies.